NADK and malignant colon neoplasm: NADK inhibitors could represent clinically relevant drugs in cancer therapy, such as the lead compound thionicotinamide, an NADK inhibitor prodrug already assayed on human B-cell lymphoma and colon cancer xenograft mice [59].